Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31089960 | 1.00 | SIGMAR1 (0.40) | SIGMAR1PRMT5DGAT1SCN9ATPH1 | |
| SCHEMBL17387449 | 0.98 | SIGMAR1 (0.39) | SIGMAR1PRMT5DGAT1SCN9ATPH1 | |
| SCHEMBL21201777 | 0.86 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL17539275 | 0.86 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL19928567 | 0.86 | SIGMAR1 (0.39) | SIGMAR1PRMT5SCN9ATPH1 | |
| SCHEMBL859685 | 0.85 | DGAT1 (0.35) | DGAT1TPH1 | |
| SCHEMBL30446012 | 0.84 | TPH1 (0.41) | SIGMAR1DGAT1SCN9ATPH1 | |
| SCHEMBL29710434 | 0.84 | TPH1 (0.41) | SIGMAR1DGAT1SCN9ATPH1 | |
| SCHEMBL18975943 | 0.83 | MAPT (0.35) | DGAT1MAPT | |
| SCHEMBL19059356 | 0.83 | SIGMAR1 (0.40) | SIGMAR1PRMT5SCN9ATPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117361825-B | Heavy metal treatment method for livestock and poultry manure | 江西正合生态农业有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117361825-A | Heavy metal treatment method for livestock and poultry manure | 江西正合生态农业有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-12622908-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4727526-A1 | TOPICAL SKIN FORMULATIONS OF A PHARMACEUTICALLY ACCEPTABLE SALT OF RUXOLITINIB | Incyte Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12564593-B2 | Topical formulation for a JAK inhibitor | INCYTE CORPORATION (US) | 2026-03-03 | — | — | US | disclosed |
| US-12544381-B2 | Topical formulation for JAK inhibitor | INCYTE CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250345337-A1 | TOPICAL FORMULATION FOR A JAK INHIBITOR | INCYTE CORP (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250255872-A1 | TOPICAL FORMULATION FOR JAK INHIBITOR | INCYTE CORPORATION | 2025-08-14 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119528911-A | Reu Ke Tie preparation method of nylon | 南通常佑药业科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2008157207-A2 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-LH-PYRAZOL-L-YL)-3- CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157207-A2 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-LH-PYRAZOL-L-YL)-3- CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312258-A1 | enzyme inhibitor for treating immune-related diseases, skin disorders, myeloid proliferative disorders, cancer; allograft rejection or graft versus host disease | INCYTE CORPORATION (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312258-A1 | enzyme inhibitor for treating immune-related diseases, skin disorders, myeloid proliferative disorders, cancer; allograft rejection or graft versus host disease | INCYTE CORPORATION (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312258-A1 | enzyme inhibitor for treating immune-related diseases, skin disorders, myeloid proliferative disorders, cancer; allograft rejection or graft versus host disease | MPST, JAK1, IL4I1 | SIGMAR1 4407/4885PRMT5 348/4885DGAT1 1090/4885 |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | SIGMAR1 4082/4885PRMT5 1304/4885DGAT1 3451/4885 |
| US-12622908-B2 | Topical formulation for a JAK inhibitor | JAK1, JAK3, JAK2 | SIGMAR1 861/4885PRMT5 1103/4885DGAT1 1542/4885 |
| US-12544381-B2 | Topical formulation for JAK inhibitor | JAK1, JAK3, STAT6 | SIGMAR1 703/4885PRMT5 2766/4885DGAT1 173/4885 |
| US-20250255872-A1 | TOPICAL FORMULATION FOR JAK INHIBITOR | JAK1, JAK3, JAK2 | SIGMAR1 2189/4885PRMT5 1054/4885DGAT1 2853/4885 |
| US-20250345337-A1 | TOPICAL FORMULATION FOR A JAK INHIBITOR | JAK1, JAK3, JAK2 | SIGMAR1 2163/4885PRMT5 901/4885DGAT1 2874/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | SIGMAR1 4550/4885PRMT5 777/4885DGAT1 3393/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | SIGMAR1 4744/4885PRMT5 724/4885DGAT1 4526/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | SIGMAR1 3460/4885PRMT5 656/4885DGAT1 3810/4885 |
| US-12564593-B2 | Topical formulation for a JAK inhibitor | JAK1, JAK3, DGKK | SIGMAR1 860/4885PRMT5 2730/4885DGAT1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.